{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:09Z","timestamp":1786993989651,"version":"build-2736575974"},"reference-count":160,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.mayocp.2026.01.017","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:02:46Z","timestamp":1775851366000},"page":"992-1012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"101","author":[{"given":"Ayo S.","family":"Falade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2026.01.017_bib2","series-title":"Diffuse large B-cell lymphoma","author":"Padala","year":"2025"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2008.07.002","article-title":"Diffuse large B-cell lymphoma","volume":"22","author":"Friedberg","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.017_bib7","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1016\/S2352-3026(20)30222-2","article-title":"A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise","volume":"7","author":"Lue","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.01.017_bib9","doi-asserted-by":"crossref","unstructured":"Younes A, Sehn LH, Johnson P, et al; PHOENIX investigators. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 37(15):1285-1295.","DOI":"10.1200\/JCO.18.02403"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.mayocp.2026.01.017_bib11","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO-25-00925","article-title":"Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma","volume":"43","author":"Morschhauser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/2040620711419001","article-title":"The molecular biology of diffuse large B-cell lymphoma","volume":"2","author":"Frick","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.017_bib13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib14","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00277-024-05880-z","article-title":"Advances in biology, diagnosis and treatment of DLBCL","volume":"103","author":"Shi","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma (DLBCL)","volume":"60","author":"Wang","year":"2023","journal-title":"Semin Hematol"},{"issue":"48","key":"10.1016\/j.mayocp.2026.01.017_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jncimonographs\/lgu010","article-title":"Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Cerhan","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2015-11-677203","article-title":"Identifying risk factors for B-cell lymphoma","volume":"127","author":"Flowers","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"6769","key":"10.1016\/j.mayocp.2026.01.017_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.mayocp.2026.01.017_bib21","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression\u2013based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"7277","key":"10.1016\/j.mayocp.2026.01.017_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u2018double hit\u2019 diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"20","key":"10.1016\/j.mayocp.2026.01.017_bib25","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib26","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.mayocp.2026.01.017_bib27","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood.2024025355","article-title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","volume":"145","author":"Tumuluru","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.017_bib28","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.mayocp.2026.01.017_bib29","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib30","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression\u2013based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.017_bib31","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/bloodadvances.2024014707","article-title":"Subgroup analysis of older patients \u226560 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study","volume":"9","author":"Hu","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.017_bib32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"suppl 3","key":"10.1016\/j.mayocp.2026.01.017_bib34","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1080\/10428190310001623775","article-title":"Gene expression profiling of diffuse large B-cell lymphoma","volume":"44","author":"Rosenwald","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.mayocp.2026.01.017_bib35","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.017_bib36","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.2020008374","article-title":"Defining and treating high-grade B-cell lymphoma, NOS","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.mayocp.2026.01.017_bib40","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2024025652","article-title":"DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma","volume":"145","author":"Chapuy","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.017_bib42","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V22.3.202532","article-title":"Best in class? DLBclass, a new classification tool for diffuse large B-cell lymphoma to facilitate development of molecular-based precision treatments","volume":"22","author":"Hill","year":"2025","journal-title":"Hematologist"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41392-025-02316-6","article-title":"Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)","volume":"10","author":"Shen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.mayocp.2026.01.017_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1301979","article-title":"A comprehensive review of the role of bone marrow biopsy and PET-CT in the evaluation of bone marrow involvement in adults newly diagnosed with DLBCL","volume":"14","author":"Alyamany","year":"2024","journal-title":"Front Oncol"},{"issue":"27","key":"10.1016\/j.mayocp.2026.01.017_bib45","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib46","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2026.01.017_bib47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mayocp.2026.01.017_bib49","series-title":"Presented at: ASH Annual Meeting and Exposition","article-title":"End-of-treatment response assessment after frontline therapy for aggressive B-cell lymphoma: landmark comparison of a singular PET\/CT scan versus ultrasensitive circulating tumor DNA","author":"Roschewski","year":"2023"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib50","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jgo.2022.02.005","article-title":"Geriatric assessment in older adults with non-Hodgkin lymphoma: a Young International Society of Geriatric Oncology (YSIOG) review paper","volume":"13","author":"Akhtar","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib51","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1038\/s41598-022-07164-w","article-title":"Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma","volume":"12","author":"Tanaka","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.mayocp.2026.01.017_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2018.10.003","article-title":"Curing diffuse large B-cell lymphomas in elderly patients","volume":"58","author":"Moccia","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2017-11-813915","article-title":"Limited-stage DLBCL: it\u2019s patient selection","volume":"131","author":"Persky","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-021-00596-z","article-title":"Evolution of therapy for limited stage diffuse large B-cell lymphoma","volume":"12","author":"Rojek","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib55","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2021013998","article-title":"Limited-stage diffuse large B-cell lymphoma","volume":"139","author":"Hawkes","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2026.01.017_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106521","article-title":"The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?","volume":"102","author":"Ba\u015fc\u0131","year":"2021","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.017_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal diffuse large B-cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.mayocp.2026.01.017_bib59","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography\u2013directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup National Clinical Trials Network study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S2","key":"10.1016\/j.mayocp.2026.01.017_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/hon.5_2879","article-title":"Early positron emission tomography response-adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): results of the phase 3 LYSA LNH 09-1B trial","volume":"39","author":"Bologna","year":"2021","journal-title":"Hematol Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2026.01.017_bib61","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib64","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2018-99-116845","article-title":"No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA Study","volume":"132","author":"Sehn","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib65","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.017_bib66","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.017_bib67","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.mayocp.2026.01.017_bib68","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography\u2013guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2026.01.017_bib69","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.01.017_bib70","series-title":"Presented at: ASH Annual Meeting and Exposition","article-title":"Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes","author":"Salles","year":"2024"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.017_bib71","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.017_bib72","first-page":"499","article-title":"Current treatment of Burkitt lymphoma and high-grade B-cell lymphomas","volume":"36","author":"Johnson","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib73","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12185-010-0728-0","volume":"92","author":"Maruyama","year":"2010","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib75","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.mayocp.2026.01.017_bib76","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1182\/bloodadvances.2022007475","article-title":"Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma","volume":"6","author":"Ferreri","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib77","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2026.01.017_bib78","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","article-title":"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib79","first-page":"448","article-title":"CODOX-M\/IVAC-R versus DA-EPOCH-R in double-hit\/triple-hit lymphoma patients aged 60 years or under","volume":"110","author":"Atallah-Yunes","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.017_bib80","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3324\/haematol.2018.195834","article-title":"Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma","volume":"104","author":"Qualls","year":"2019","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.mayocp.2026.01.017_bib82","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood.2023020168","article-title":"How I treat secondary CNS involvement by aggressive lymphomas","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib83","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2021.278613","article-title":"Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy","volume":"109","author":"Roschewski","year":"2023","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.mayocp.2026.01.017_bib84","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib85","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.017_bib86","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib88","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0003-4266(05)82113-4","article-title":"Non Hodgkin\u2019s lymphoma involving the adrenal glands and the central nervous system (CNS): a particular evolution after chemotherapy","volume":"66","author":"V\u00e9layoudom","year":"2005","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib89","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bjh.14325","article-title":"Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement","volume":"175","author":"El-Galaly","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdm471","article-title":"Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group","volume":"19","author":"Ryan","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.017_bib91","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","article-title":"Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse","volume":"96","author":"Villa","year":"2011","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.mayocp.2026.01.017_bib92","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood.2019003277","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial","volume":"135","author":"Sch\u00f6der","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.017_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100018","article-title":"Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial","volume":"1","author":"D\u00fchrsen","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminhematol.2023.12.003","article-title":"Integration of PET in DLBCL","volume":"60","author":"Lewis","year":"2023","journal-title":"Semin Hematol"},{"issue":"23","key":"10.1016\/j.mayocp.2026.01.017_bib95","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2016-05-672196","article-title":"Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?","volume":"129","author":"Le Gouill","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib96","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"S2","key":"10.1016\/j.mayocp.2026.01.017_bib97","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.3163_112","article-title":"MRD-negativity after frontline DLBCL therapy: pooled analysis of 6 clinical trials","volume":"41","author":"Roschewski","year":"2023","journal-title":"Hematol Oncol"},{"issue":"17","key":"10.1016\/j.mayocp.2026.01.017_bib98","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2022007706","article-title":"Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation","volume":"7","author":"Merryman","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2023-187650","article-title":"Prognostic utility of minimal residual disease (MRD) after curative intent induction therapy for DLBCL: a prospective real-world ctDNA study","volume":"142","author":"Sworder","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2024-199813","volume":"144","author":"Stepan","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.017_bib101","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1016\/j.clml.2025.05.003","article-title":"Minimal residual disease testing for diffuse large B cell lymphoma","volume":"25","author":"Atout","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.017_bib102","article-title":"ALPHA3: a pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy","volume":"43","author":"Westin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.mayocp.2026.01.017_bib103","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1200\/JCO.23.00570","article-title":"Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma","volume":"41","author":"Hilton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2026.01.017_bib104","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/bloodadvances.2024012760","article-title":"Defining primary refractory large B-cell lymphoma","volume":"8","author":"Bock","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib105","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood-2021-146206","article-title":"Time to refractory status defines subsets of primary refractory diffuse large B-cell lymphoma with distinct outcomes","volume":"138","author":"Bock","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib106","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s00280-002-0447-1","article-title":"Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue","volume":"49","author":"Hagemeister","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"36","key":"10.1016\/j.mayocp.2026.01.017_bib107","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.mayocp.2026.01.017_bib108","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.017_bib109","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line\u2014a population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.mayocp.2026.01.017_bib111","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2026.01.017_bib112","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.mayocp.2026.01.017_bib114","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.017_bib116","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib117","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2026.01.017_bib118","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2026.01.017_bib119","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib120","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib121","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300213","article-title":"CAR T-cell immunotherapy in minority patients with lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib122","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib123","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.017_bib124","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2026.01.017_bib125","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.017_bib127","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib128","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2024-203668","article-title":"Plamotamab: first presentation of subcutaneous administration in a phase 1 dose escalation study in heavily pretreated R\/R NHL patients who had prior CAR-T cell therapy","volume":"144","author":"Riedell","year":"2024","journal-title":"Blood"},{"issue":"10466","key":"10.1016\/j.mayocp.2026.01.017_bib129","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.mayocp.2026.01.017_bib130","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1200\/JCO-25-01957","article-title":"mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase III SUNMO trial","volume":"43","author":"Budde","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.017_bib131","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib132","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.017_bib133","first-page":"2186","article-title":"Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy","volume":"109","author":"Tun","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib134","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib135","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib136","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib137","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.017_bib138","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib139","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.017_bib140","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtct.2023.09.008","article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis","volume":"29","author":"Derigs","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib141","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtct.2022.10.026","article-title":"Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma","volume":"29","author":"Fried","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib142","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-025-01702-5","article-title":"Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: recent advances and emerging therapies","volume":"18","author":"Bock","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.mayocp.2026.01.017_bib143","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/aol.2019.06.01","article-title":"Risk stratification and management algorithms for patients with diffuse large B-cell lymphoma and CNS involvement","volume":"3","author":"Calimeri","year":"2019","journal-title":"Ann Lymphoma"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.017_bib144","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1016\/S1470-2045(22)00371-0","article-title":"CNS prophylaxis for diffuse large B-cell lymphoma","volume":"23","author":"Eyre","year":"2022","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.mayocp.2026.01.017_bib145","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.017_bib146","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1200\/JCO.2025.43.16_suppl.7052","article-title":"Impact of cell of origin, gene rearrangements, and frontline treatment on incidence of secondary central nervous system lymphoma in newly diagnosed diffuse large B-cell lymphoma","volume":"43","author":"Falade","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.017_bib147","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.017_bib148","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.017_bib149","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"Weidmann","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib150","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.mayocp.2026.01.017_bib151","series-title":"R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, \u226580 years, or frail \u226575 years\u2014an open label randomized Nordic Lymphoma Group phase III trial","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib152","doi-asserted-by":"crossref","first-page":"3123.2","DOI":"10.1182\/blood-2024-199784","article-title":"S2207: Randomized phase II study of the addition of targeted agents to tafasitamab-lenalidomide in transplant ineligible patients with relapsed\/refractory LBCL","volume":"144","author":"Amengual","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2026.01.017_bib153","author":"Haiyan"},{"key":"10.1016\/j.mayocp.2026.01.017_bib154","series-title":"A phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit\/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9)","author":"ADC Therapeutics","year":"2025"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib155","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1182\/blood-2022-157761","volume":"140","author":"Friedberg","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.017_bib156","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00277-021-04689-4","article-title":"Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study","volume":"101","author":"Paunescu","year":"2022","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.017_bib157","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/cancers17040711","article-title":"Health-related quality of life in long-term survivors of non-Hodgkin lymphoma: a French population-based study","volume":"17","author":"Wasse","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.mayocp.2026.01.017_bib158","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.01.017_bib159","series-title":"Non-Hodgkin\u2019s Lymphoma: Diagnosis and Management","article-title":"Follow-up of DLBCL","year":"2016"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.017_bib160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-141982","article-title":"The value of follow-up following complete remission with frontline chemotherapy for DLBCL","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.017_bib161","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.mayocp.2019.05.011","article-title":"Surveillance in patients with diffuse large B cell lymphoma","volume":"95","author":"Kallam","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.017_bib162","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.27577","article-title":"Limited benefit of routine clinical follow-up for relapse detection in diffuse large B-cell lymphoma patients in complete remission following first-line treatment","volume":"100","author":"Lassen","year":"2025","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.017_bib163","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626173418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626173418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:39:20Z","timestamp":1781743160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626173418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":160,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0025619626173418"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.01.017","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}